SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 4c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Lantern Pharma (LTRN) files for 2.24M share offering by selling stockholders